About us
We are developing advanced biotechnological solutions designed to enhance healthcare outcomes.
Our partners are key players in the biotechnology and healthcare industries, including leading research institutions, universities.
Our partners are key players in the biotechnology and healthcare industries, including leading research institutions, universities.
Pipeline
We have developed three effective programs that help treat complex diseases
Androgenetic alopecia & Prostate cancer
(androgen receptor gene therapy)
(androgen receptor gene therapy)
Psoriasis(NFKB inhibitor zeta
gene therapy)
gene therapy)
target optimisation
target optimisation
proof of concept
IND
Clinical
proof of concept
IND
Clinical
Various cancers (AXL Tyrosine Kinase inhibitors)
Pipeline
target optimisation
proof of concept
IND
Clinical
Clinical
IND
proof of concept
target optimisation
Retinitis pigmentosa (RPGR replacement gene therapy)
our programs
AR-001
Indication: Androgenetic alopecia, androgen-dependent prostate cancer
Stage: Proof of concept
Description:
shRNA-based gene therapy for downregulating the AR (androgen receptor) gene expression.
About 50% of men and 30% of women experience alopecia by the age of 50. Prostate cancer is the second most commonly diagnosed cancer among men and the fifth leading cause of cancer deaths worldwide. The androgen receptor plays a key role in the pathogenesis of both diseases in most cases. We are developing a local shRNA-based therapy aimed at effectively reducing AR gene expression with minimal systemic effects.
Stage: Proof of concept
Description:
shRNA-based gene therapy for downregulating the AR (androgen receptor) gene expression.
About 50% of men and 30% of women experience alopecia by the age of 50. Prostate cancer is the second most commonly diagnosed cancer among men and the fifth leading cause of cancer deaths worldwide. The androgen receptor plays a key role in the pathogenesis of both diseases in most cases. We are developing a local shRNA-based therapy aimed at effectively reducing AR gene expression with minimal systemic effects.
INF-002
Indication: Psoriasis
Stage: Target optimisation
Description:
Approximately 2-3% of the global population is affected by psoriasis. We selected a panel of genes that play crucial roles in inflammatory pathways within the skin and are known to be upregulated in psoriatic patients. By silencing these genes, we aim to reduce the production of pro-inflammatory cytokines, thereby alleviating or potentially eliminating the symptoms of psoriasis. We are currently testing this panel of candidate genes by inhibiting their expression using shRNA to develop the most effective topical therapy for this condition
Stage: Target optimisation
Description:
Approximately 2-3% of the global population is affected by psoriasis. We selected a panel of genes that play crucial roles in inflammatory pathways within the skin and are known to be upregulated in psoriatic patients. By silencing these genes, we aim to reduce the production of pro-inflammatory cytokines, thereby alleviating or potentially eliminating the symptoms of psoriasis. We are currently testing this panel of candidate genes by inhibiting their expression using shRNA to develop the most effective topical therapy for this condition
Next Generation AXL Kinase inhibitors
Stage: Proof of concept
AXL is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain.
AXL is widely expressed in many organs:
• Macrophages
• Endothelial cells
• Heart
• Liver and skeletal muscle
AXL signaling controls:
• EMT
• Survival
• Motility
• Invasion
• Metastasis development.
AXL is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain.
AXL is widely expressed in many organs:
• Macrophages
• Endothelial cells
• Heart
• Liver and skeletal muscle
AXL signaling controls:
• EMT
• Survival
• Motility
• Invasion
• Metastasis development.
Retinitis pigmentosa (XLRP)
Indication: X-linked retinitis pigmentosa (XLRP)
Stage: Proof of concept
Description:
X-linked retinitis pigmentosa (XLRP) is estimated to affect 2.7 to 3.5 males per 100,000, primarily due to mutations in the RPGR gene, the most common cause of XLRP. This severe condition leads to dysfunction of photoreceptor connecting cilia, resulting in progressive degeneration and loss of photoreceptor cells, ultimately causing vision loss. Our therapeutic goal is to deliver normal RPGR gene copies to the retina via an AAV vector to slow or halt this degeneration.
Stage: Proof of concept
Description:
X-linked retinitis pigmentosa (XLRP) is estimated to affect 2.7 to 3.5 males per 100,000, primarily due to mutations in the RPGR gene, the most common cause of XLRP. This severe condition leads to dysfunction of photoreceptor connecting cilia, resulting in progressive degeneration and loss of photoreceptor cells, ultimately causing vision loss. Our therapeutic goal is to deliver normal RPGR gene copies to the retina via an AAV vector to slow or halt this degeneration.
OUR TEAM
-
Boris Mayzel -
Pjotr G. KnyazevHead of Science -
Egor BezelHead of Business Development
If you want to learn more about our projects and explore potential collaboration - feel free to contact us at
egor.bezel@bstbio.de
E-mail:
